Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
1. A compound of Formula (I):
wherein the compound of Formula (I) is prepared by a process comprising the following steps:
(1) reducing a compound of the following formula:
in the presence of H 2 and a palladium catalyst, to provide a compound of the following formula:
and
(2) coupling the compound provided in step (1) above with a compound of Formula (II):
in the presence of a palladium catalyst, to provide the compound of Formula (I):
2. A process for preparing a compound of Formula (I):
wherein the process comprises the following steps:
(1) reducing a compound of the following formula:
in the presence of H 2 and a palladium catalyst, to provide a compound of the following formula:
and
(2) coupling the compound provided in step (1) above with a compound of Formula (II):
in the presence of a palladium catalyst, to provide the compound of Formula (I):
3. The process of claim 2 , wherein reducing comprises hydrogenating in the presence of Pd—C.
4. The process of claim 2 , wherein coupling comprises palladium-catalyzed cross coupling with Pd 2 (dba) 2 .
5. A compound:
6. A compound: